Doubling down on oncology, Sanofi buys into a new checkpoint inhibitor with a $125M down payment
On its latest shopping trip through the immuno-oncology department, Sanofi picked up the rights to a checkpoint inhibitor from Biond Biologics’ pipeline, paying over $1 billion to add the clinic-bound program to its growing cancer lineup.
The French pharma will shell out $125 million in cash upfront, with the potential for another $1 billion in milestones plus “tiered double digit” royalties, for BND-22, a humanized, IgG4 antagonist antibody that goes after the ILT2 receptor. Israel-based Biond is leading a Phase 1a study — which is expected to launch by mid-2021 — and Sanofi will take the program from there.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
